<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146328</url>
  </required_header>
  <id_info>
    <org_study_id>1182.17</org_study_id>
    <nct_id>NCT00146328</nct_id>
  </id_info>
  <brief_title>Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects</brief_title>
  <official_title>A Long Term Open Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the long term safety and tolerability of multiple
      oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the
      development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other
      antiretroviral medications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Haemoglobin</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - White Blood Cell ct.</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Platelets</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Prothrombin Time</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Sodium</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Potassium</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Calcium</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Phosphate</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Carbon Dioxide</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Aspartate Aminotransferase (AST/GOT,SGOT)</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alanine Aminotransferase (ALT/GPT,SGPT)</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alkaline Phosphatase</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Amylase</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Creatine Phosphokinase</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Lipase</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Glucose</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Cholesterol, Total</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Creatinine</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Bilirubin, Total</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Triglycerides</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Uric Acid</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Albumin</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 -Low-density Lipoprotein (LDL)</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Adverse Events Leading to Death</measure>
    <time_frame>End of Trial (&gt;288 weeks)</time_frame>
    <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Human Immunodeficiency Virus-Ribonucleic Acid (HIV-RNA) Viral Load - Last Observation Carried Forward (LOCF)</measure>
    <time_frame>Baseline to 192-240 week time interval</time_frame>
    <description>Change from baseline in Human Immunodeficiency Virus-Ribonucleic Acid (HIV-RNA) viral load with last observation carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count (LOCF)</measure>
    <time_frame>Baseline to 192-240 week time interval</time_frame>
    <description>Change from baseline in CD4 cell count with last observation carried forward(LOCF).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">997</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients With Varying Degrees of Tipranavir Treatment Experience</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Highly Tipranavir Treatment Experienced Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tipranavir Treatment Naive Patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          1. Ability and willingness to give written informed consent in accordance with
             institutional and federal guidelines and to comply with the investigational nature of
             the study and the related requirements.

          2. All subjects must have successfully completed participation in a combination
             tipranavir/ritonavir trial or have confirmed virologic failure in the 1182.12 or
             1182.48 trials and are not able to obtain TPV by prescription. Successful completion
             of participation is defined as conclusion of required subject-weeks on assigned dosing
             (trial specific) and completion of required visits.

          3. Male and female subjects 18 years and over.

          4. Presence of Human Immunodeficiency Virus 1 (HIV-1) infection as documented by any
             licensed Enzyme Linked immunosorbent Assay (ELISA) test kit and confirmed by Western
             Blot, or HIV-1 culture, or HIV-1 antigen, or plasma HIV 1 Ribonucleic Acid (RNA) or a
             second antibody test by a method other than ELISA at any time prior to study entry.

          5. Adherence to previous tipranavir/ritonavir dosing protocol and adherence to visit
             requirements of previous protocol (as assessed by principal investigator).

          6. Acceptable screening laboratory values that indicate adequate baseline organ function.
             Laboratory values are considered to be acceptable if the following apply:

               -  Total Cholesterol ≤400 mg/dl (&lt;Common Toxicity Criteria (CTC) Grade 2).

               -  Total Triglycerides ≤750 mg/dl (&lt;Division of AIDS (DAIDS) Grade 2).

               -  Alanine aminotransferase (ALT) ≤3.0x upper limit of normal (ULN) and Aspartate
                  aminotransferase (AST) ≤2.5x ULN (&lt;DAIDS Grade 1).

               -  Any Grade Gamma Glutamyl transpeptidase(GGT) is acceptable.

               -  Any Grade creatinine kinase is acceptable as long as there is no concurrent
                  myopathy.

               -  All other laboratory test values ≤DAIDS Grade 1.

        EXCLUSION CRITERIA

          1. Female subjects who are of reproductive potential who:

               -  Have a positive serum beta human chorionic gonadotropin (B HCG) at
                  Screening/Enrollment Visit.

               -  Are not willing to use a reliable method of barrier contraception (such as
                  diaphragm or condoms).

               -  Are breast-feeding.

          2. Subjects who are actively using injection drugs or other substance abuse (such as
             extensive alcohol or narcotic use) which is considered by the investigator to be a
             significant impairment to health and to protocol adherence.

          3. Any medical condition(s) which, in the opinion of the investigator, would interfere
             with the subject's ability to participate in or adhere to the requirements of this
             protocol.

          4. History of any illness or drug allergy which, in the opinion of the investigator,
             might confound the results of the study or pose additional risk in administering
             tipranavir/ritonavir to the subject.

          5. Active use of any of the following:

               -  Investigational HIV-1 vaccines.

               -  Any new investigational antiretroviral agent that was not approved for use in the
                  patients prior tipranavir trial.

               -  Medications excluded during the trial period (see Section 4.2).

               -  Herbal medications (e.g., St. John's Wort).

          6. Active HIV-related or non HIV-related illness that may be negatively affected by use
             of tipranavir/ritonavir as determined by the investigator.

             If a subject must temporarily discontinue tipranavir/ritonavir at the recommendation
             of the investigator (at the completion of the previous tipranavir trial), then the
             subject may enroll in 1182.17 once the clinical illness has resolved, and after
             approval from the Boehringer Ingelheim Clinical Monitor or Local Clinical Monitor.

          7. Clinically significant liver disease in the 90 days prior to baseline visit,
             regardless of baseline AST and/or ALT values.

          8. Hypersensitivity to tipranavir or ritonavir.

          9. Voluntary discontinuation of antiretroviral therapy (including tipranavir/ritonavir)
             for more than seven days from completion of previous tipranavir trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1182.17.39 MDS Pharma Services</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.75 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.89 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.60 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.15 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.40 Tower ID Medical</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.46 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.47 University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.73 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.128 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.37 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.58 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.96 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.87 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.43 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.65 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.126 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.8 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.22 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.64 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.51 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.125 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.132 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.76 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.52 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.77 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.69 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.136 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.70 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.36 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.32 University of Kansas School of Medicine - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.21 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.30 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.67 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.86 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.63 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.74 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.6 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.62 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.59 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.118 Early Intervention Program (EIP) Clinic</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.93 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.24 Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.34 ID Care, Inc.</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.50 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.79 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.105 Pollari Medical Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.130 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3 Division of Infectious Diseases</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.42 Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.7 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.94 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.135 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.31 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.53 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.54 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.134 Summa Health System</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.95 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.26 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.9 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.99 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.23 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.11 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.18 Vanderbilt AIDS Clinical Trials Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.142 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.16 Nelson-Tebedo Clinic</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.122 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.68 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.97 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.10 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.92 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.100 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5401 Fundacion Huesped</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5402 Funcei</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5403 consultorio externo &quot;PETS&quot;</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5404 Infectología</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5405 Dpto. de Enfermedades infecciosas (Pabellón 22)</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5406 Pabellón de Clínicas 2° Piso</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.401 St. Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.402 Taylor Square Private Clinic</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.405 AIDS Research Initiative</name>
      <address>
        <city>DarlingHurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.407 Holdsworth House General Practice</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.408 407 Doctors Pty Ltd.</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.403 Albion Street Clinic</name>
      <address>
        <city>Surry Hills</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.404 Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3209 Instituut Tropische Geneeskunde</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3210 Centre Hospitalier de Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5511 Universidade Federal da Bahia</name>
      <address>
        <city>Canela - Salvador - BA</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5508 I.I. Emilio Ribas</name>
      <address>
        <city>Cerqueira César, São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5509 (Unidade de Testes Terapêuticos)</name>
      <address>
        <city>Cidade Nova - Rio de Janeiro - RJ</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5502 Farmácia do Instituto de Pesquisa Evandro Chagas</name>
      <address>
        <city>Manguinhos - Rio de Janeiro - RJ</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5505 Instituto A-Z de Pesquisa e Ensino da PUC</name>
      <address>
        <city>Mercês - Curitiba - PR</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5507 Hospital Geral de Nova Iguaçu - Ministério da Saúde</name>
      <address>
        <city>Nova Iguaçu - Rio de Janeiro - RJ</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5501 Hospital Dia</name>
      <address>
        <city>Sacoma - São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5503 Instituto de Infectologia Emílio Ribas</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5504 Enfermaria de MI</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5510 Casa de AIDS</name>
      <address>
        <city>São Paulo, SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5506 Centro de Referência e Treinamento - DST/AIDS</name>
      <address>
        <city>Vila Mariana, Sao Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.902 Downtown Infectious Diseases Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.913 McMaster University Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.901 Division of Infectious Diseases</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.905 Canadian Immunodeficiency Research Collaborative Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.906 Infectious Diseases &amp; HIV - St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.907 University Health Network - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.910 Sunnybrook &amp; Women's College Health Science Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.914 Montreal General Hospital - McGill University Health Centre</name>
      <address>
        <city>Monteal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.903 Montreal Chest Institute, McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.904 Clinique Medicale Du Quartier Latin</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.915 Clinique medicale l'Actuel</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus N</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Copenhagen Ø</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33011 Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33019 Hôpital Saint André</name>
      <address>
        <city>Bordeaux cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33020 Hôpital Côte de Nacre</name>
      <address>
        <city>Caen cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33007 Hôpital Antoine Beclere</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33008 Hôpital de l'Hôtel Dieu</name>
      <address>
        <city>Lyon cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33023 Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33012 Hôpital de la Conception</name>
      <address>
        <city>Marseille cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33013 Hôpital Sainte Marguerite</name>
      <address>
        <city>Marseille cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.00336 Hôpital Hôtel Dieu</name>
      <address>
        <city>Nantes cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33010 Hôpital de l'Archet</name>
      <address>
        <city>Nice cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33024 Groupe Hospitalier Cochin</name>
      <address>
        <city>Paris cedex 14</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33022 Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris cedex 15</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.00335 Hôpital Bichat Claude Bernard</name>
      <address>
        <city>Paris cedex 18</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.00331 Hôpital Tenon</name>
      <address>
        <city>Paris cedex 20</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.00333 Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.00334 Hôpital de la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33014 Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33018 Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33016 Hôpital Civil</name>
      <address>
        <city>Strasbourg cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.00332 Hôpital du Chalucet</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33017 Hôpital Brabois Adultes</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.33021 Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4911 Arzt für Innere Medizin</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4901 Epimed GmbH c/o</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4902 Charite, Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4918 Rheinische Friedrich-Wilhelm-Universität</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4906 ID-Ambulanz Klinikum Dortmund</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4912 Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4914 Arzt für Innere Medizin</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4908 Universitätskliniken Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4904 Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4924 Klinikum der J. W.-Goethe-Universität</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4930 Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg/Breisgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4928 Facharzt für Innere Medizin/Rheumatologie</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4916 Medizinisches Versorgungszentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4929 Universitätsklinikum Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4931 IPM Study Center GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4920 Abteilung Klinische Immunologie</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4909 Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4905 Universitätsklinik Köln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4926 Internist</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4923 Facharzt für Innere Medizin,</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4907 Medizinische Poliklinik</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4910 MUC Research GmbH</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4915 Klinium Natruper Holz</name>
      <address>
        <city>Osnabrück</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4921 Arzt für Allgemeinmedizin</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0409 Ospedale Santa Maria Annunziata</name>
      <address>
        <city>Antella (fi)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0413 Ospedale di Circolo di Busto</name>
      <address>
        <city>Busto Arsizio (va)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0384 Azienda Ospedaliera Arcispedale S. Anna</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0397 Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0412 S.C. Malattie Infettive</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0411 Presidio Ospedaliero &quot;A. Manzoni&quot;</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0389 Reparto Malattie Infettive</name>
      <address>
        <city>Macerata</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0393 Fondazione Centro S. Raffaele del Monte Tabor</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0386 Policlinico Universitario</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0388 Ospedale A. Cotugno</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0385 IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0394 IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0395 Azienda Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0419 I Cattedra Malattie Infettive</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0387 Ospedale Amedeo di Savoia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0398 Ospedale Amedeo di Savoia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.0415 U.O.A. Malattie Infettive B</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5201 Centro Médico La Raza IMSS</name>
      <address>
        <city>Col. La Raza, Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5203 Hospital Civil Nuevo de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.5206 Centro Medico San Vicente</name>
      <address>
        <city>Monterrey, N.l., Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.3502 Hospital Condes Castro Guimarães</name>
      <address>
        <city>Cascais</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.705 Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.701 Hospital Clínico y Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.703 Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.704 Hospital Ramón y Cajal.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.710 Hospital Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.712 Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.717 Hospital Clínico Universitario Vírgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.713 Hospital Universitario Vírgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.714 Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.720 Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.718 Complejo Hospitalario Xeral - Cíes</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4101 DIM / Abteilung für Infektiologie</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4104 Département de médicine interne Div. Des maladies infectieus</name>
      <address>
        <city>Genève</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4103 DIM / Abteilung für Infektiologie</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4102 Departement für Innere Medizin</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4411 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4414 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4418 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.17.4407</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2005</study_first_submitted>
  <study_first_submitted_qc>September 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <results_first_submitted>May 26, 2009</results_first_submitted>
  <results_first_submitted_qc>May 26, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2009</results_first_posted>
  <last_update_submitted>January 31, 2014</last_update_submitted>
  <last_update_submitted_qc>January 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
          <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (Highly Treatment Experienced Patients)</title>
          <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
        </group>
        <group group_id="P3">
          <title>Group 3 (Tipranavir naïve Patients)</title>
          <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="291"/>
                <participants group_id="P2" count="255"/>
                <participants group_id="P3" count="449"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="291"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="79"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Virologic Failure/lack of efficacy</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="142"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial ended/site closed</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient decision to end</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enroll into other trial</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Interaction with other medication</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
          <description>A total of 995 patients who entered 1182.17 from a 'core' TPV/r trial were treated with TPV/r and were included in the integrated database. Of the 995 patients from 241 sites in 19 countries worldwide, 291 patients were categorized into Group 1. Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 (Highly Treatment Experienced Patients)</title>
          <description>A total of 995 patients who entered 1182.17 from a 'core' TPV/r trial were treated with TPV/r and were included in the integrated database. Of the 995 patients from 241 sites in 19 countries worldwide, 255 patients were categorized into Group 2. Group 2: Patients from 1182.51 who rolled over into 1182.17.</description>
        </group>
        <group group_id="B3">
          <title>Group 3 (Tipranavir naïve Patients)</title>
          <description>A total of 995 patients who entered 1182.17 from a 'core' TPV/r trial were treated with TPV/r and were included in the integrated database. Of the 995 patients from 241 sites in 19 countries worldwide, 449 patients were categorized into Group 3. Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="291"/>
            <count group_id="B2" value="255"/>
            <count group_id="B3" value="449"/>
            <count group_id="B4" value="995"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" spread="8"/>
                    <measurement group_id="B2" value="45.6" spread="8.2"/>
                    <measurement group_id="B3" value="43.5" spread="7.7"/>
                    <measurement group_id="B4" value="44.1" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="405"/>
                    <measurement group_id="B4" value="896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Haemoglobin</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Haemoglobin</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="-2.41" upper_limit="-0.30"/>
                    <measurement group_id="O2" value="2" lower_limit="-1.56" upper_limit="-0.17"/>
                    <measurement group_id="O3" value="6" lower_limit="-1.37" upper_limit="-0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - White Blood Cell ct.</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - White Blood Cell ct.</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Platelets</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Platelets</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Prothrombin Time</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Prothrombin Time</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Sodium</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Sodium</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Potassium</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Potassium</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Calcium</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Calcium</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Phosphate</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Phosphate</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Carbon Dioxide</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Carbon Dioxide</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Aspartate Aminotransferase (AST/GOT,SGOT)</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Aspartate Aminotransferase (AST/GOT,SGOT)</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alanine Aminotransferase (ALT/GPT,SGPT)</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alanine Aminotransferase (ALT/GPT,SGPT)</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alkaline Phosphatase</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alkaline Phosphatase</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Amylase</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Amylase</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Creatine Phosphokinase</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Creatine Phosphokinase</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Lipase</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Lipase</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Glucose</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Glucose</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Cholesterol, Total</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Cholesterol, Total</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Creatinine</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Creatinine</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Bilirubin, Total</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Bilirubin, Total</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Triglycerides</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Triglycerides</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Uric Acid</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Uric Acid</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Albumin</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Albumin</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 -Low-density Lipoprotein (LDL)</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 -Low-density Lipoprotein (LDL)</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Adverse Events Leading to Death</title>
        <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>End of Trial (&gt;288 weeks)</time_frame>
        <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events Leading to Death</title>
          <description>NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>FAS17 - Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48 Group 2: Patients from 1182.51 who rolled over into 1182.17 Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and who then rolled into 1182.17</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Human Immunodeficiency Virus-Ribonucleic Acid (HIV-RNA) Viral Load - Last Observation Carried Forward (LOCF)</title>
        <description>Change from baseline in Human Immunodeficiency Virus-Ribonucleic Acid (HIV-RNA) viral load with last observation carried forward (LOCF)</description>
        <time_frame>Baseline to 192-240 week time interval</time_frame>
        <population>FAS17 with last observation carried forward (LOCF, missing were replaced by the previous non-missing value), Group 1: TPV/r patients from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48; Group 2: Patients from 1182.51; Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and rolled into 1182.17</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Human Immunodeficiency Virus-Ribonucleic Acid (HIV-RNA) Viral Load - Last Observation Carried Forward (LOCF)</title>
          <description>Change from baseline in Human Immunodeficiency Virus-Ribonucleic Acid (HIV-RNA) viral load with last observation carried forward (LOCF)</description>
          <population>FAS17 with last observation carried forward (LOCF, missing were replaced by the previous non-missing value), Group 1: TPV/r patients from Trials 1182.2, 1182.4, 1182.6, 1182.52, 1182.12 and 1182.48; Group 2: Patients from 1182.51; Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed and rolled into 1182.17</population>
          <units>Log 10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" lower_limit="-2.41" upper_limit="0.30"/>
                    <measurement group_id="O2" value="-0.62" lower_limit="-1.56" upper_limit="-0.17"/>
                    <measurement group_id="O3" value="-0.5" lower_limit="-1.37" upper_limit="-0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count (LOCF)</title>
        <description>Change from baseline in CD4 cell count with last observation carried forward(LOCF).</description>
        <time_frame>Baseline to 192-240 week time interval</time_frame>
        <population>FAS17 with last observation carried forward (LOCF, missing were replaced by the previous non-missing value), Group 1: TPV/r patients from Trials 1182.2, 1182.4,1182.6, 1182.52, 1182.12 and 1182.48; Group 2: Patients from 1182.51; Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
            <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Highly Treatment Experienced Patients)</title>
            <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Tipranavir naïve Patients)</title>
            <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Cell Count (LOCF)</title>
          <description>Change from baseline in CD4 cell count with last observation carried forward(LOCF).</description>
          <population>FAS17 with last observation carried forward (LOCF, missing were replaced by the previous non-missing value), Group 1: TPV/r patients from Trials 1182.2, 1182.4,1182.6, 1182.52, 1182.12 and 1182.48; Group 2: Patients from 1182.51; Group 3: PI comparator arm patients from 1182.4, 1182.12 and 1182.48 who virologically failed.</population>
          <units>cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="253"/>
                <count group_id="O3" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="178"/>
                    <measurement group_id="O2" value="26" spread="149"/>
                    <measurement group_id="O3" value="21" spread="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 288 weeks. From the time patients received their first dose of TPV/r until the last patient out of the study on 26 May 2008 (for those patients who entered Trial 1182.17).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (Patients With Varying Degrees of Treatment Experience</title>
          <description>Group 1: TPV/r patients who rolled over from Trials 1182.2, 1182.4, 1182.6, 1182.52 (NCT00275444, NCT00034866), 1182.12 (NCT00054717) and 1182.48 (NCT00144170). A total of 291 patients were categorized into Group 1.</description>
        </group>
        <group group_id="E2">
          <title>Group 2 (Highly Treatment Experienced Patients)</title>
          <description>Group 2: Patients from 1182.51 (NCT00056641) who rolled over into 1182.17. A total of 255 patients were categorized into Group 2.</description>
        </group>
        <group group_id="E3">
          <title>Group 3 (Tipranavir naïve Patients)</title>
          <description>Group 3: PI comparator arm patients from 1182.4, 1182.12 (NCT00054717) and 1182.48 (NCT00144170) who virologically failed and who then rolled into 1182.17. A total of 449 patients were categorized into Group 3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100"/>
                <counts group_id="E2" subjects_affected="91"/>
                <counts group_id="E3" subjects_affected="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lymphoid tissue hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Fanconi syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lip ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Polyserositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Immune reconstitution syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Immunodeficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AIDS dementia complex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>AIDS encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Acanthamoeba infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Acquired immunodeficiency syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Anorectal cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Campylobacter intestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Choriomeningitis lymphocytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cryptosporidiosis infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Encephalitis cytomegalovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Encephalitis herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>End stage AIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Gastritis fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Herpes oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Necrotising herpetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Sinusitis aspergillus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Viral sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Biopsy breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Fungus serology test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Liver scan abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Fat redistribution</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Bone erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Anal cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Anal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Bowenoid papulosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Burkitt's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Colorectal carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Malignant anorectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Penis carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Plasmablastic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Splenic neoplasm malignancy unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Intracranial hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hallucination, tactile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Focal glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis proliferative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Nephritis interstitial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Renal tubular acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Renal tubular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Fallopian tube obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Haematosalpinx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Snoring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lipodystrophy acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lipohypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Colostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Intestinal operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lymphadenectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Wisdom teeth removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Air embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Necrosis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="284"/>
                <counts group_id="E2" subjects_affected="250"/>
                <counts group_id="E3" subjects_affected="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lipodystrophy acquired</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Pharmaceuticals</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

